Oncolytics announces positive preclinical results for pelareorep with pan-RAS inhibitor in colorectal cancer

ONCOLYTICS BIOTECH INC

Pelareorep + pan-RAS inhibitor reduced tumor growth vs control in RAS-driven colorectal cancer model.
Greatest tumor reductions in RAS inhibitor and combination groups; no antagonism between therapies.
Findings support further evaluation of optimized pelareorep dosing with RAS inhibitors to delay resistance.
Company plans expanded preclinical studies across dosing schedules and RAS-driven tumor models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.